Filing Details

Accession Number:
0001104659-23-124302
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-07 16:16:44
Reporting Period:
2023-12-05
Accepted Time:
2023-12-07 16:16:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1649904 Rhythm Pharmaceuticals Inc. RYTM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1636385 C Hunter Smith 222 Berkeley Street, 12Th Floor
Boston MA 02116
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-05 7,026 $6.88 68,432 No 4 M Direct
Common Stock Disposition 2023-12-05 7,026 $35.06 61,406 No 4 S Direct
Common Stock Acquisiton 2023-12-06 20,000 $6.88 81,406 No 4 M Direct
Common Stock Disposition 2023-12-06 20,000 $40.00 61,406 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-12-05 7,026 $0.00 7,026 $6.88
Common Stock Stock Option (Right to Buy) Disposition 2023-12-06 20,000 $0.00 20,000 $6.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
131,094 2027-08-08 No 4 M Direct
111,094 2027-08-08 No 4 M Direct
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2022.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $35.00 to $35.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The stock options is fully vested.